Project Grant SLMAQM12GR1017

Nano Pharmasolutions, Inc. received a $275,961 Project Grant award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041). The grant funds the development of a novel nanoformulation drug delivery platform to address challenges associated with poorly soluble drugs. The goal is to improve drug solubility and bioavailability through innovative formulation approaches. The one-year project period runs from August 1, 2021...

Federal Grant Award Summary Cypress Biopharma, Inc. received a $611,572 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, through August 31, 2026. The award supports the development of a novel non-immunosuppressive therapeutic approach for childhood nephrotic syndrome (NS) by leveraging a highly active metabolite of...

This Cooperative Agreement award from the Food and Drug Administration (FDA) under the Food and Drug Administration Research program (CFDA 93.103) provides $150,000 in funding to the Pharmaceutical Inspection Co-Operation Scheme-Association De Droit Suisse to develop curricula and training tools for a web-based educational center called the PIC/S Inspectorates' Academy (PIA). The goal is to harmonize and standardize Good Manufacturing Practice (GMP) training and qualification processes for...

The National Institute of Standards and Technology (NIST) awarded Infratrac Inc., a woman-owned small business, a $400,000 Cooperative Agreement under CFDA 11.620 - Science, Technology, Business and/or Education Outreach. The purpose of the award is for Infratrac to build upon its prior Phase I research demonstrating an integrated system using non-destructive technology with the potential to enhance trust and safety for 3D printed drugs. Under the Phase II project, Infratrac will focus on...

Federal Project Grant Award Summary The American Society of Health-System Pharmacists Inc. (ASHP) received a $3.0 million Project Grant from the Food and Drug Administration's Center for Drug Evaluation and Research under the Food and Drug Administration Research program (CFDA 93.103), awarded September 25, 2025, with completion targeted for August 31, 2028. The project delivers a comprehensive vulnerability assessment and mitigation strategy focused on identifying drugs susceptible to...

Federal Grant Award Summary Respirerx Pharmaceuticals Inc. received a $3.0 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on September 23, 2025, with completion scheduled for August 31, 2027. This Small Business Innovation Research (SBIR) Phase II direct award supports the development of KRM-II-81, a novel gamma-aminobutyric acid...

The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...

The National Science Foundation (NSF) awarded a $951,394 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Ballydel Technologies Inc. for the development of serialized anti-counterfeit labeling technology for pharmaceutical and biological products. The project aims to create a scalable manufacturing process for imprinting covert, encrypted patterns onto labels for individual vaccine vials, incorporating serialized codes to enable traceability...

Summary of Federal Cooperative Agreement Award Akyso Therapeutics, LLC (doing business as The Drug Delivery Co LLC) received a $2.93 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop an extended-release buprenorphine implant for treating opioid use disorder (OUD). The award, effective August 1, 2025, through July 31, 2027, supports the development of a bioabsorbable, subcutaneous implant...

Federal Grant Award Summary Taxis Pharmaceuticals Inc. received a $1.0M Small Business Innovation Research (SBIR) Phase 2 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 16, 2025, with a completion date of April 30, 2028. The award supports lead optimization and development of an oral dihydrofolate reductase (DHFR) inhibitor therapeutic to treat multidrug-resistant Neisseria...